Edith A Perez

Edith A Perez

UNVERIFIED PROFILE

Are you Edith A Perez?   Register this Author

Register author
Edith A Perez

Edith A Perez

Publications by authors named "Edith A Perez"

Are you Edith A Perez?   Register this Author

100Publications

3728Reads

11Profile Views

Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial.

Pharmacogenet Genomics 2017 Oct;27(10):378-385

aHealth Sciences Research Departments of bCancer Biology cCardiovascular Diseases dHematology/Oncology, Mayo Clinic, Jacksonville, Florida eHealth Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000302DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581215PMC
October 2017

Breast cancer brain metastases: Molecular subtype, treatment and survival.

Breast Dis 2016 ;36(4):133-141

Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BD-160237DOI Listing
March 2017

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

J Clin Oncol 2017 Jan 7;35(2):141-148. Epub 2016 Nov 7.

Edith A. Perez, Mayo Clinic, Jacksonville, FL; Howard Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Jennifer A. Petersen, Genentech, South San Francisco, CA; Carlos Barrios, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre, Brazil; Wolfgang Eiermann, Interdisciplinary Oncology Center, Munich, Germany; Masakazu Toi, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Young-Hyuck Im, Samsung Medical Centre, Seoul, Korea; Pierfranco Conte, University of Padova and Istituto Oncologico Veneto, Padova, Italy; Miguel Martin, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Tadeusz Pienkowski, Postgraduate Medical Education Center, Warsaw, Poland; Xavier Pivot, University Hospital Jean Minjoz, Besançon, France; Sven Stanzel, Alexander Strasak, Monika Patre, F. Hoffmann-La Roche, Basel, Switzerland; and Paul Ellis, Guys Hospital and Sarah Cannon Research Institute, London, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.4887
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.4887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455677PMC
January 2017

Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.

J Clin Oncol 2016 10;34(29):3502-3510

Mithun Vinod Shah, Anne E. Wiktor, Reid G. Meyer, Kathleen S. Tenner, Karla V. Ballman, Stefan J, Green, William R. Sukov, Rhett P. Ketterling, Robert B. Jenkins, Mayo Clinic, Rochester, MN; and Edith A. Perez, Mayo Clinic, Jacksonville, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.8983DOI Listing
October 2016

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

J Natl Cancer Inst 2016 08 20;108(8). Epub 2016 Apr 20.

Department of Medicine, Breast European Adjuvant Study Team (BrEAST) Data Centre, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium (AS, EdA, MP, HAAJr); Frontier Science (Scotland) Ltd, Grampian View, Kincraig, Kingussie, UK (DAt, IB, CC); Novartis Pharmaceuticals Corporation, East Hanover, NJ (YH); Alliance Statistics and Data Center, Mayo Clinic, Section of Biostatistics, Scottsdale, AZ (ACD); Sunnybrook Odette Cancer Centre, the University of Toronto and the NCIC Clinical Trials Group, Toronto, Ontario, Canada (KIP); The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD (ACW); Sana Klinikum Offenbach, Offenbach, Germany (CJ); National Institute of Oncology, Budapest, Hungary (IL); Helios Klinikum Berlin-Buch, Berlin, Germany (MU); Royal Marsden Hospital NHS Trust, Sutton/Surrey, UK (IS); Patricia Ritchie Centre for Cancer Care and Research, The University of Sydney, Mater Hospital, North Sydney, Australia (FB); Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China (BX); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (HG); Mayo Clinic, Jacksonville, FL (EAP)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017935PMC
August 2016

Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.

Cancer J 2015 Sep-Oct;21(5):357-64

From the *Breast Cancer Research, Sarah Cannon Research Institute; and †Medical Oncology, Tennessee Oncology, PLLC, Nashville, TN; ‡Dana-Farber Cancer Institute, Boston, MA; §Smilow Cancer Center, Yale University, New Haven, CT; ∥AdvancedBC.org, New York, NY; ¶Genentech, Inc, South San Francisco, CA; and #Mayo Clinic, Jacksonville, FL.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/journalppo/2015/09000/Trastuzum
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000144DOI Listing
June 2016

Reply to C. Shah et al.

J Clin Oncol 2016 05 21;34(15):1824-5. Epub 2016 Mar 21.

University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.4714DOI Listing
May 2016

Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries.

PLoS One 2015 28;10(5):e0128345. Epub 2015 May 28.

Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0128345PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447406PMC
April 2016

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

J Clin Oncol 2016 Apr 23;34(10):1034-42. Epub 2015 Nov 23.

Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016PMC
April 2016

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.

Support Care Cancer 2016 Mar 23;24(3):1219-26. Epub 2015 Aug 23.

Department of General Internal Medicine, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-015-2915-2DOI Listing
March 2016

Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.

J Clin Oncol 2016 Feb 21;34(6):581-7. Epub 2015 Sep 21.

Pooja P. Advani, Gerardo Colon-Otero, and Edith A. Perez, Mayo Clinic, Jacksonville, FL; and Karla V. Ballman and Travis J. Dockter, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.8413DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980566PMC
February 2016

Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order.

Authors:
Edith A Perez

Drug Resist Updat 2016 Jan 10;24:13-22. Epub 2015 Nov 10.

Mayo Clinic Cancer Center, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drup.2015.11.001DOI Listing
January 2016

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.

Breast Cancer Res Treat 2015 Dec 14;154(3):509-20. Epub 2015 Nov 14.

Department of Oncology, Leeds Institute of Cancer and Pathology, and St James's Institute of Oncology, University of Leeds, Leeds, LS9 7TF, England, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3633-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661183PMC
December 2015

Reply to P.G. Gavin et al.

J Clin Oncol 2015 Nov 17;33(31):3672-3. Epub 2015 Aug 17.

Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.6051DOI Listing
November 2015

Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.

J Clin Oncol 2015 Nov 14;33(33):3938-44. Epub 2015 Sep 14.

Lawrence J. Solin, Albert Einstein Healthcare Network, Philadelphia; Nancy E. Davidson, University of Pittsburgh, Pittsburgh, PA; Robert Gray, Dana-Farber Cancer Institute; Abram Recht, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston; Mary Ann Lowen, Baystate Medical Center, Springfield, MA; Lorie L. Hughes, Harris Radiation Therapy Center at Gordon Hospital, Calhoun; William C. Wood, Emory University, Atlanta, GA; Sunil S. Badve, Indiana University, Indianapolis, IN; Frederick L. Baehner, University of California, San Francisco, San Francisco, CA; James N. Ingle, Mayo Clinic, Rochester, MN; Edith A. Perez, Mayo Clinic, Jacksonville, FL; and Joseph A. Sparano, Montefiore Medical Center, Bronx, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.8588DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652014PMC
November 2015

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

N Engl J Med 2015 Nov 27;373(21):2005-14. Epub 2015 Sep 27.

From the Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); Sunnybrook Research Institute, Toronto (K.I.P.) and Juravinski Cancer Center, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Medical Center, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), Duke University Medical Center, Durham (J.A.O.), Wake Forest University Health Service, Winston-Salem (L.I.W.), and Southeast Clinical Oncology Research Consortium, Goldsboro (J.N.A.) - all in North Carolina; Mayo Clinic, Jacksonville, FL (E.A.P.); University of Maryland School of Medicine, Baltimore (J.A.O.), and National Institutes of Health, Bethesda (J.Z., T.L.) - both in Maryland; Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.) - both in Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Baylor College of Medicine, Houston (M.J.E.), and University of Texas, San Antonio (P.R.) - both in Texas; Washington University, St. Louis (M.J.E.); Allegheny General Hospital (S.P.) and University of Pittsburgh (A.M.B.) - both in Pittsburgh; the Department of Medical Oncology and Breast Center, Yonsei University College of Medicine, Seoul, South Korea (S.P.); Emory University, Atlanta (W.C.W.); Irish Clinical Oncology Research Group, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); University of Hawaii Cancer Center, Honolulu (J.L.B.); and Stanford University, Stanford, CA (G.W.S.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510764DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701034PMC
November 2015

The Globalization of Cooperative Groups.

Semin Oncol 2015 Oct 10;42(5):693-712. Epub 2015 Jul 10.

Chair, SWOG; Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health & Science University and Knight Cancer Institute, Portland, OR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.07.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592942PMC
October 2015

HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.

Biomark Med 2015 ;9(1):35-49

Division of Hematology & Oncology, Mayo Clinic, 4500 San Pablo Road S., Jacksonville, FL 32224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/bmm.14.95DOI Listing
September 2015

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation.

J Natl Compr Canc Netw 2015 Sep;13(9):1066-70

From Mayo Clinic, Jacksonville, Florida; Monogram Biosciences/LabCorp, South San Francisco, California; Foundation Medicine, Cambridge, Massachusetts; and University of Maryland Greenebaum Cancer Center, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://www.jnccn.org/content/13/9/1066.full.pdf
Web Search
http://dx.doi.org/10.6004/jnccn.2015.0132DOI Listing
September 2015

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

J Clin Oncol 2015 Aug 22;33(24):2600-8. Epub 2015 Jun 22.

Ciara C. O'Sullivan and Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Ian Bradbury, Christine Campbell, and Eileen Holmes, Frontier Science, Inverness-shire, Scotland; Marc Spielmann and Suzette Delaloge, Institut de Cancérologie Gustave Roussy, Villejuif, France; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Heikki Joensuu, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Joseph P. Costantino and Priya Rastogi, University of Pittsburgh, Pittsburgh, PA; Dimitrios Zardavas, Breast International Group; Karla V. Ballman, Mayo Clinic, Rochester, MN; Evandro de Azambuja and Martine Piccart-Gebhart, Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium; and Richard D. Gelber, Harvard Medical School, Harvard T.H. Chan School of Public Health, Dana-Farber Cancer Institute, and Frontier Science and Technology Research Foundation, Boston, MA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534523PMC
http://dx.doi.org/10.1200/JCO.2015.60.8620DOI Listing
August 2015

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).

J Clin Oncol 2015 Jul 8;33(21):2361-9. Epub 2015 Jun 8.

Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; William T. Barry, Alliance Statistics and Data Center, Dana-Farber Cancer Institute; Erica L. Mayer and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Alvaro Moreno-Aspitia and Edith A. Perez, Mayo Clinic, Jacksonville, FL; Alan P. Lyss, Heartland Cancer Research Community Clinical Oncology Program; Michael Naughton, Washington University School of Medicine, St Louis, MO; Constance Cirrincione and Eleanor Leung, Alliance Statistics and Data Center, Duke University, Durham; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; Deborah Toppmeyer, Cancer Institute of New Jersey, New Brunswick, NJ; and Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.5298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500830PMC
July 2015

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

J Clin Oncol 2015 Jul 15;33(21):2353-60. Epub 2015 Jun 15.

Joseph A. Sparano, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY; Fengmin Zhao and Jennifer A. Ligibel, Dana-Farber Cancer Institute-Harvard University, Boston, MA; Silvana Martino, John Wayne Cancer Institute, Santa Monica, CA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Tom Saphner, Vince Lombardi Cancer Center, Two Rivers, WI; Antonio C. Wolff, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; George W. Sledge Jr, Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN; William C. Wood, Winship Cancer Center, Emory University, Atlanta, GA; and Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/21/2353.full.pdf
Web Search
http://jco.ascopubs.org/content/early/2015/06/15/JCO.2015.60
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.60.9271
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.60.9271DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500829PMC
July 2015

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

J Clin Oncol 2015 Mar 20;33(7):701-8. Epub 2015 Jan 20.

Edith A. Perez, E. Aubrey Thompson, Yan W. Asmann, and Xochiquetzal J. Geiger, Mayo Clinic, Jacksonville, FL; Karla V. Ballman, S. Keith Anderson, Krishna R. Kalari, Jeanette E. Eckel-Passow, Kathleen S. Tenner, Jin Jen, Beiyun Chen, Robert B. Jenkins, and Monica M. Reinholz, Mayo Clinic, Rochester, MN; Amylou C. Dueck, and Ann E. McCullough, Mayo Clinic, Scottsdale, AZ; Jian-Bing Fan, Illumina, San Diego, CA; George W. Sledge, Stanford School of Medicine, Palo Alto, CA; Eric P. Winer, Harvard Medical School, Boston, MA; and Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.6298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334774PMC
March 2015

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.

J Clin Oncol 2015 Feb 20;33(6):594-601. Epub 2015 Jan 20.

Peter A. Kaufman, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Martin S. Olivo, Yi He, and Corina E. Dutcus, Eisai, Woodcliff Lake, NJ; Ahmad Awada, Medical Oncology Clinic, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Chris Twelves and Galina Velikova, Leeds Institute of Cancer and Pathology, and St James's Institute of Oncology, Leeds, United Kingdom; Louise Yelle, University of Montreal, Montreal, Quebec, Canada; and Javier Cortes, Vall D'Hebron University Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.4892DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463422PMC
February 2015

Erratum: Dual HER2 blockade: preclinical and clinical data.

Breast Cancer Res 2014 Nov 6;16(6):468. Epub 2014 Nov 6.

Division of Hemotology and Oncology, College of Medicine, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL, 32224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-014-0468-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303199PMC
November 2014

Practice-changing data in metastatic breast cancer.

Authors:
Edith A Perez

Clin Adv Hematol Oncol 2013 ;11(10 Suppl 16):7-12

Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, Florida.

View Article

Download full-text PDF

Source
November 2014

New developments in metastatic breast cancer: general discussion.

Clin Adv Hematol Oncol 2013 ;11(10 Suppl 16):16-7

View Article

Download full-text PDF

Source
November 2014

New developments in metastatic breast cancer: integrating recent data into clinical practice.

Clin Adv Hematol Oncol 2013 ;11(10 Suppl 16):1-18; quiz 19

University of California San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
November 2014

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

J Clin Oncol 2014 Nov 20;32(33):3744-52. Epub 2014 Oct 20.

Edith A. Perez, Gerardo Colon-Otero, the Mayo Clinic, Jacksonville; Eleftherios Mamounas, University of Florida Health Cancer Center-Orlando Health, Orlando, FL; Edward H. Romond, University of Kentucky, Lexington, KY; Vera J. Suman, Mayo Clinic, Rochester, MN; Jong-Hyeon Jeong, Priya Rastogi, University of Pittsburgh; Nancy E. Davidson, University of Pittsburgh Cancer Institute; Norman Wolmark, Allegheny General Hospital, Pittsburgh, PA; George Sledge, Stanford University School of Medicine, Stanford; Silvana Martino, The Angeles Clinic and Research Institute, Santa Monica, CA; Charles E. Geyer Jr, Virginia Commonwealth University Massey Cancer Center, Richmond, VA; Julie Gralow, University of Washington/Seattle Cancer Care Alliance, Seattle, WA; Sandra M. Swain, MedStar Washington Hospital Center, Washington, DC; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jo Anne Zujewski, National Institutes of Health, Rockville, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.5730DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805PMC
November 2014

Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.

J Natl Cancer Inst 2014 Oct 12;106(10). Epub 2014 Sep 12.

Northwestern University Feinberg School of Medicine, Chicago, IL (JCS, JRT, CBW, KPS, AWR, JDP, ABB, WJG); Center for Business Models in Healthcare, Chicago, IL (JRT, CBW); UCSF Center for Translational and Policy Research on Personalized Medicine, Department of Clinical Pharmacy, University of California, San Francisco, CA (JRT); Department of Pathology, Dartmouth Hitchcock Medical Center and the Audrey and Theodor Geisel School of Medicine, Dartmouth College, Lebanon, NH (GJT); Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, FL (EAP).* Current affiliation: Spectrum Health Medical Group, Grand Rapids, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176043PMC
October 2014

Perspectives from the American Society of Clinical Oncology 2014 Conference: breast cancer highlights.

Future Oncol 2014 Oct;10(12):1897-9

Department of Hematology & Oncology, Mayo Clinic, Jacksonville, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.151DOI Listing
October 2014

Dual HER2 blockade: preclinical and clinical data.

Breast Cancer Res 2014 Aug 1;16(4):419. Epub 2014 Aug 1.

Division of Hemotology and Oncology, College of Medicine, Mayo Clinic, 4500 San Pablo Rd S., Jacksonville, FL, 32224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-014-0419-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429364PMC
August 2014

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

J Clin Oncol 2014 Aug 16;32(22):2311-7. Epub 2014 Jun 16.

Lawrence N. Shulman, Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Donald A. Berry, MD Anderson Cancer Center, Houston, TX; Constance T. Cirrincione, Gretchen Kimmick, Duke University Medical Center, Durham; Hyman Muss, University of North Carolina at Chapel Hill, Chapel Hill, NC; Heather P. Becker, University of Chicago, Chicago, IL; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Ruth O'Regan, Emory University, Atlanta, GA; Silvana Martino, The Angeles Clinic and Research Institute, Los Angeles, CA; Charles L. Shapiro, The James Cancer Center, Ohio State University, Columbus, OH; Charles J. Schneider, Christiana Healthcare Services, Wilmington, DE; Larry Norton, Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.7142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105484PMC
August 2014

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

J Clin Oncol 2014 Jul 5;32(19):2078-99. Epub 2014 May 5.

Sharon H. Giordano and Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Cancer Institute, New York, NY; Jennie R. Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Ian Krop, Nancy U. Lin, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jennifer Levinson, Ponte Vedra Beach; Edith A. Perez, Mayo Clinic, Jacksonville; Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando, FL; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.0948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076031PMC
July 2014

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

J Clin Oncol 2014 Jul 5;32(19):2100-8. Epub 2014 May 5.

Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Edith A. Perez, Mayo Clinic, Jacksonville; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Cancer Institute, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Sharon H. Giordano and Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Ian Krop, Eric P. Winter, and Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/32/19/2100.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.0955
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.0955DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366342PMC
July 2014

Highlights in breast cancer from the 2014 American Society of Clinical Oncology® annual meeting.

Authors:
Edith A Perez

Clin Adv Hematol Oncol 2014 Jul;12(7):451-3

Mayo Clinic Cancer Center, Jacksonville, Florida.

View Article

Download full-text PDF

Source
July 2014

HER2 testing: current status and future directions.

Cancer Treat Rev 2014 Mar 11;40(2):276-84. Epub 2013 Sep 11.

Mayo Clinic, 4500 San Pablo Rd., Jacksonville, FL 32224, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2013.09.001DOI Listing
March 2014

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Arch Pathol Lab Med 2014 Feb 7;138(2):241-56. Epub 2013 Oct 7.

Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pitsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2013-0953-SADOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086638PMC
February 2014

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

J Clin Oncol 2013 Nov 7;31(31):3997-4013. Epub 2013 Oct 7.

Antonio C. Wolff, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth H. Hammond, University of Utah School of Medicine and Intermountain Healthcare, Salt Lake City, UT; David G. Hicks, University of Rochester Medical Center, Rochester, NY; Mitch Dowsett, Royal Marsden Hospital, London, United Kingdom; Kimberly H. Allison, Stanford University Medical Center, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Donald C. Allred, Washington University School of Medicine, St Louis, MO; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada; Michael Bilous, University of Western Sydney and Healthscope Pathology, Sydney, New South Wales, Australia; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Patricia A. Spears, North Carolina State University, Raleigh, NC; Gail H. Vance, Indiana University Medical Center, Indianapolis, IN; Giuseppe Viale, University of Milan, European Institute of Oncology, Milan, Italy; and Daniel F. Hayes, University of Michigan Comprehensive Cancer Care Center, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.9984DOI Listing
November 2013

Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Clin Cancer Res 2013 Oct 21;19(20):5798-807. Epub 2013 Aug 21.

Authors' Affiliations: Section of Biostatistics; Division of Anatomic Pathology, Mayo Clinic, Scottsdale, Arizona; Division of Experimental Pathology, Department of Laboratory Medicine and Pathology; Division of Biomedical Statistics and Informatics and Medical Oncology, Mayo Clinic, Rochester, Minnesota; Division of Anatomic Pathology and Hematology/Oncology, Mayo Clinic, Jacksonville, Florida; Division of Hematology/Oncology, University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, Pennsylvania; The Angeles Clinic and Research Institute, Santa Monica, California; Indiana University Medical Center Cancer Pavilion, Indianapolis, Indiana; Division of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa; Seattle Cancer Care Alliance, Seattle, Washington; and Case Western Reserve University, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805021PMC
October 2013

Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.

Cancer 2013 Sep 17;119(17):3113-22. Epub 2013 Jun 17.

VeriTech Corporation, Mercer Island, Washington; University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28196DOI Listing
September 2013

Individualizing treatment to optimize survival outcomes in breast cancer.

Clin Adv Hematol Oncol 2013 Aug;11 Suppl 10(8):3-21

The West Clinic Memphis, TN.

View Article

Download full-text PDF

Source
August 2013

New treatment paradigms for optimizing survival in advanced and metastatic breast cancer.

Clin Adv Hematol Oncol 2012 Aug;10(8 Suppl 13):1-14; quiz 15-6

Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, Florida, USA.

View Article

Download full-text PDF

Source
August 2012